The specific product segments analyzed are Enzyme Immunoassay Systems, Fluorescence Immunoassay Systems, Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay Systems.
the "Company") (NASDAQ: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic systems and high intensity focused ultrasound products, today announced that it has completed the development of 10 new enhanced chemiluminescence immunoassay ("ECLIA") infertility diagnostic reagents, increasing the Company's reagent kit offering to a total of 72.
is a China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostics products using enhanced chemiluminescence immunoassay ("ECLIA") technology to detect and monitor various diseases and disorders and high intensity focused ultrasound ("HIFU") tumor therapy systems for the treatment of solid cancers and benign tumors.
the "Company") (NASDAQ: CMED), a leading China-based medical device company that develops, manufactures and markets high intensity focused ultrasound products and advanced in-vitro diagnostic systems, today announced that it has successfully completed the development of four liver fibrosis diagnostic reagents that use enhanced chemiluminescence immunoassay ("ECLIA") technology.
the "Company") (NASDAQ: CMED), a leading China-based medical device company that develops, manufactures and markets high intensity focused ultrasound products and advanced in-vitro diagnostic systems, today announced that it has successfully completed the development of two Down syndrome diagnostic reagents that use chemiluminescence immunoassay technology.
We aim to broaden our reagent offering to a total of 70 kits within the next 12 months, which will make us one of the leading providers of chemiluminescence immunoassay reagents in the industry worldwide" Financial Results China Medical reported net revenues of RMB131.
the "Company") (NASDAQ: CMED), a leading China-based medical device company that develops, manufactures and markets high intensity focused ultrasound products and advanced in-vitro diagnostic systems, today announced that it has successfully completed the development of two HIV diagnostic reagents (the "HIV reagents") using chemiluminescence immunoassay technology for both HIV initial screening and HIV definitive diagnosis.
The specific product segments analyzed are Enzyme Immunoassay Analyzer, Fluorescence Immunoassay Analyzer, Chemiluminescence Immunoassay Analyzer, Radio Immunoassay Analyzer, and Nephelometric Immunoassay Analyzer.
